Cowen analyst Chris Shibutani remains sidelined, but optimistic on Lexicon Pharmaceuticals (NASDAQ:LXRX) after the firm released a positive top-line readout from InTandem2, the second of its three pivotal Phase III trials …
In a research report released yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target, …
In a research report published yesterday, Wedbush analyst Liana Moussatos reiterated an Outperform rating on Lexicon Pharmaceuticals (LXRX) with a $4 price target …